nixiFLOR^®: One Dose.  Dual Action.  

Key benefits

• One convenient dose
• Combines antimicrobial and anti-inflammatory power
• Rapid symptom relief
• Expected results - visible improvement due to fever reduction
• Transparent pricing without complicated programs
• Same trusted formula.  Better value.
  
  
  

Product Details:

• Indications:  nixiFLOR^® is indicated for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and control of BRD - associated pyrexia in beef and non-lactating dairy cattle.
• Concentration: nixiFLOR^® is an injectable solution of the synthetic antibiotic florfenicol and the non-steroidal anti-inflammatory drug (NSAID) flunixin. Each milliliter of sterile nixiFLOR^® contains 300 mg florfenicol, 16.5 mg flunixin as flunixin meglumine, 300 mg 2-pyrrolidone, 35 mg malic acid, and triacetin qs.
• Dosage & Administration: nixiFLOR^® should be administered once by subcutaneous injection at a dose rate of 40 mg florfenicol/kg body weight and 2.2 mg flunixin/kg body weight (6 mL/100 lb.). Do not administer more than 10 mL at each site. The injection should be given only in the neck. Injection sites other than the neck have not been evaluated. 
• Residue Warnings:  Animals intended for human consumption must not be slaughtered within 38 days of treatment.  This product is not approved for use in female dairy cattle 20 months of age of older, including dry dairy cows.  Us in these cattle may cause drug residues in milk and/or in calves born to these cows.  A withdrawal period has not been established in pre-ruminating calves.  Do not use in calves to be processed for veal.
• Not for use in animals intended for breeding purpose.  The effects of florfenicol and flunixin meglumine on bovine reproductive performance, pregnancy, and lactation have not been determined.  Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy.  NSAIDs are known to have potential effects on both parturition and the estrous cycle.  There may be a delay in the onset of estrus it flunixin is administered during the prostaglandin phase of the estrous cycle.  Studies have associated the use of flunixin in cattle with a delay in parturition and prolonged labor (which may increase the risk of stillbirth), and interference with involution and expulsion of fetal membranes (which may increase the risk for placental retention and metritis).
  Florfenicol and flunixin meglumine, when administered as directed, may induce a transient reaction at the injection and underlying tissues that may result in trim loss of edible tissue at slaughter.
• Adverse Reactions:  Transient inappetence, diarrhea, decreased water consumption, and injection site swelling have been associated with the use of florfenicol in cattle.  In addition, anaphylaxis and collapse have been reported post-approval with the use of another formulation of florfenicol in cattle.
• Packaging: Available in 250 mL and 500 mL vials
• Precautions: nixiFLOR^® is not intended for human use and should be kept out of the reach of children. The label contains complete use information, including cautions and warnings. Always read, understand and follow the label and use directions

For more information, view the full label, consult with your local herd health veterinarian or contact a Parnell technical services representative.